agilon health, inc. (AGL) stock plummeted 16.25% in the after-hours trading session on Tuesday, following the company's disappointing fourth quarter 2024 earnings results and weak guidance for the upcoming fiscal year 2025.
While the healthcare services company reported revenue of $1.52 billion for Q4 2024, in line with expectations, its earnings metrics fell short. agilon health reported an adjusted loss of $0.26 per share, wider than analysts' estimates of a $0.23 per share loss. More concerningly, the company's adjusted EBITDA of -$83.97 million significantly lagged expectations of -$69.92 million.
Perhaps more worrisome for investors was agilon health's outlook for fiscal 2025. The company provided revenue growth guidance of just -2.2% year-over-year at the midpoint, a sharp deceleration from the 40.7% growth achieved in fiscal 2024. agilon health's projected 2025 EBITDA guidance of -$75 million also fell short of analyst expectations, highlighting continued profitability challenges amid what management termed a "challenging Medicare Advantage environment."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.